Cetuximab: a review of its use in squamous cell carcinoma of the head and neck
JE Frampton - Drugs, 2010 - Springer
Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …
Cetuximab in the treatment of squamous cell carcinoma of the head and neck
P Specenier, JB Vermorken - Expert review of anticancer therapy, 2011 - Taylor & Francis
The majority of the head and neck cancers are squamous cell carcinomas, which commonly
overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that …
overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that …
[HTML][HTML] Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer
MB Hannouf, C Sehgal, JQ Cao, JD Mocanu… - PloS one, 2012 - journals.plos.org
Purpose To assess the cost effectiveness of adding cetuximab to platinum-based
chemotherapy in first-line treatment of patients with recurrent or metastatic head and neck …
chemotherapy in first-line treatment of patients with recurrent or metastatic head and neck …
Targeted anti-cancer therapy in the elderly
W Gonsalves, AK Ganti - Critical reviews in oncology/hematology, 2011 - Elsevier
Cancer is a disease of the elderly with the majority of new diagnoses and deaths from
cancer occurring in persons greater than 65 years of age. A major goal of cancer therapy, in …
cancer occurring in persons greater than 65 years of age. A major goal of cancer therapy, in …
Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck
N van der Linden, CWM van Gils, CP Pescott… - European Archives of …, 2015 - Springer
Clinical trial EMR 62202-006 demonstrates prolonged median locoregional control (24.4 vs.
14.9 months), progression-free survival (17.1 vs. 12.4 months) and overall survival (49.0 vs …
14.9 months), progression-free survival (17.1 vs. 12.4 months) and overall survival (49.0 vs …
[PDF][PDF] Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First
MB Hannouf, C Sehgal, JQ Cao, JD Mocanu… - 2012 - academia.edu
Purpose: To assess the cost effectiveness of adding cetuximab to platinum-based
chemotherapy in first-line treatment of patients with recurrent or metastatic head and neck …
chemotherapy in first-line treatment of patients with recurrent or metastatic head and neck …